TBI & post-concussion recovery
Adjunct considerations for users navigating mild TBI, persistent post-concussion symptoms, or moderate-severe TBI recovery alongside a neurology and rehabilitation team.
What changes during this transition
Recovery from TBI is multidisciplinary rehab, full stop. The strongest evidence-based intervention for prolonged concussion symptoms is sub-symptom-threshold aerobic exercise (Leddy 2019, Buffalo Concussion Treatment Trial), paired with vestibular rehab for dizziness, neuropsych for cognitive symptoms, and physical or occupational therapy as the injury severity dictates. SSRIs and SNRIs have a real role in post-TBI depression. For moderate-severe TBI, the acute and subacute care is neurosurgery and ICU management; for mild TBI and persistent post-concussion symptoms, the long arc is rehab. Peptides are adjuncts at best, and the picks here reflect that hierarchy. Cerebrolysin is the strongest TBI signal in this library — registered for TBI as an explicit indication in 50+ countries, with two properly-powered cross-jurisdictional RCTs (CAPTAIN-I and CAPTAIN-II) supporting Glasgow Outcome Scale Extended improvement at 90 days in moderate-severe presentations. Administration is IV or IM, clinic-supervised, on a defined cycle, in coordination with the neurology and rehab team — it is not a take-home peptide. Semax is a registered Russian prescription medicine for cerebrovascular indications with a smaller-cohort clinical literature in subacute mild-to-moderate TBI; the tier reflects the absence of independent multicenter replication outside the source jurisdiction, not the quality of the Russian work. B12-methylcobalamin earns a place because confirmed B12 deficiency masquerading as post-TBI cognitive impairment or fatigue is a documented scenario worth ruling out — especially in the veteran TBI population where deficiency prevalence is elevated. What's not in the browse picks: BPC-157 and TB-500. Both are heavily marketed in community 'concussion stacks,' both rest on preclinical rodent CNS-injury work without any human TBI trial or human TBI pharmacokinetics, and both have vasoactive or angiogenic mechanisms that point in the wrong direction during the acute-to-subacute TBI window when cerebral autoregulation is impaired. The substrate entries exist so /ask can answer honestly when users raise these peptides — and the answer is honest about the gap between the rodent work and the human claim. TB-500 is additionally WADA S2-prohibited, which is a hard regulatory stop for the collision-sport athlete population most likely to ask. The peptides surfaced here are coordinated with a treating neurologist or rehabilitation team — none of them belong in self-directed protocols, and the rehab program is the dominant intervention in every case.
Important caveat
Chronic traumatic encephalopathy (CTE) is a post-mortem diagnosis — it cannot be treated in vivo, and no peptide prevents or reverses it. The intervention for repeat-impact populations (collision sports, military blast exposure, MMA, boxing) is stopping further exposure. Post-TBI epilepsy is a real long-term risk (~5-15% after moderate-severe TBI; lower but elevated after mild), and new headache patterns, mood changes, or seizure-like activity require neurology follow-up, not peptide adjustment. Second-impact syndrome and cerebral edema are the highest-stakes concerns in the first weeks after injury, and uncharacterized vasoactive or angiogenic interventions in that window are inappropriate. Sub-symptom-threshold aerobic exercise plus targeted rehab is the dominant evidence-based intervention. All peptide use here belongs in coordination with the neurology and rehabilitation team, not as a parallel self-directed protocol.
Peptides editorially relevant to tbi & post-concussion recovery
3 peptides from the library — each evidence-tiered honestly.
- CerebrolysinTier 2
Porcine-derived neuropeptide mixture
Multi-peptide cocktail from porcine brain, manufactured by EVER Pharma. Approved in Europe / Asia / Russia for ischemic stroke, dementia, and TBI. NOT US-approved. Tier 1/2 abroad in approved indications; Tier 3 for off-label use.
- SemaxTier 3
Synthetic ACTH(4-10) analog (heptapeptide)
Russian-developed nootropic and neuroprotective peptide. Registered there as a prescription product for stroke; most of the clinical evidence is Russian-language and not independently replicated outside that body of work.
- B12 (Methylcobalamin)Tier 1
Vitamin (methylcobalamin)
Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.